Logo image of FLXN

HORIZON FLEXIBLE INCOME ETF (FLXN) Stock Overview

USA - NYSEARCA:FLXN - US44053A5231 - ETF

25.76 USD
+0.08 (+0.29%)
Last: 10/24/2025, 8:25:33 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to FLXN. FLXN was compared to 534 industry peers in the Biotechnology industry. Both the profitability and financial health of FLXN have multiple concerns. FLXN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

FLXN Yearly Net Income VS EBIT VS OCF VS FCFFLXN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 -50M -100M -150M

1.2 Ratios

The profitability ratios for FLXN are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FLXN Yearly ROA, ROE, ROICFLXN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 200 400 600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FLXN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FLXN Yearly Profit, Operating, Gross MarginsFLXN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 -10K -20K -30K

More info and screens

0

2. Health

2.1 Basic Checks

FLXN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FLXN has been increased compared to 1 year ago.
FLXN has about the same debt/assets ratio as last year.
FLXN Yearly Shares OutstandingFLXN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 10M 20M 30M 40M
FLXN Yearly Total Debt VS Total AssetsFLXN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 100M 200M 300M 400M

2.2 Solvency

Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC9.18%
FLXN Yearly LT Debt VS Equity VS FCFFLXN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 100M -100M 200M

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A
FLXN Yearly Current Assets VS Current LiabilitesFLXN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FLXN Yearly Revenue VS EstimatesFLXN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
FLXN Yearly EPS VS EstimatesFLXN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
FLXN Price Earnings VS Forward Price EarningsFLXN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FLXN Per share dataFLXN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FLXN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HORIZON FLEXIBLE INCOME ETF

NYSEARCA:FLXN (10/24/2025, 8:25:33 PM)

25.76

+0.08 (+0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-17 2021-11-17
Earnings (Next)03-09 2022-03-09/amc
Inst OwnersN/A
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap1.29B
Revenue(TTM)N/A
Net Income(TTM)N/A
Analysts78.67
Price TargetN/A
Short Float %0%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-Date08-22 2025-08-22 (0.145849)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)N/A
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpSN/A
BVpSN/A
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset TurnoverN/A
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio N/A
Quick Ratio N/A
Altman-Z N/A
F-ScoreN/A
WACC9.18%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

HORIZON FLEXIBLE INCOME ETF / FLXN FAQ

Can you describe the business of HORIZON FLEXIBLE INCOME ETF?

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. The company is headquartered in Burlington, Massachusetts and currently employs 257 full-time employees. The company went IPO on 2014-02-12. The firm is focused on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), the common form of arthritis. Its product candidate, ZILRETTA, is the intra-articular (IA) injection indicated for the management of OA knee pain. The company is approved by Food and Drug Administration (FDA) to manage osteoarthritis knee pain. The ZILRETTA is a non-opioid therapy that employs its microsphere technology to provide pain relief. The company markets ZILRETTA to prescribing physicians through its own field sales force of Musculoskeletal Business Managers (MBMs). The firm's other product candidates include FX201 and FX301. The FX201 is an IA gene therapy product candidate in clinical development for the treatment of OA. The FX301 is developed as a locally administered peripheral analgesic nerve block for management of post-operative pain.


What is the stock price of HORIZON FLEXIBLE INCOME ETF today?

The current stock price of FLXN is 25.76 USD. The price increased by 0.29% in the last trading session.


What is the ChartMill technical and fundamental rating of FLXN stock?

FLXN has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


Would investing in HORIZON FLEXIBLE INCOME ETF be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on FLXN.